Scilex Holding Company reported that ZTlido, its non-opioid pain treatment, is now the most prescribed by pain specialists, with a market share increase from 11.8% to 14.2% year-over-year in October. Year-to-date gross sales for ZTlido through November 2023 are estimated between $125.0 million to $135.0 million, a significant increase from $84.6 million in the same period of 2022. The projected full year gross sales for 2023 are expected to be between $140.0 million to $150.0 million, marking an estimated growth of 46% to 56% compared to $96.0 million in 2022.